Zhenglong Li
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Gualou-Xiebai-derived Apigenin-7-O-glucoside inhibits VSMCs foam cell formation and alleviates atherosclerosis by targeting Rab7 to drive SNAP29-dependent lipophagy.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: May 20, 2026
Gualou total alkaloids improve lipid metabolism and alleviate atherosclerosis by inhibiting hepatic PLA2G2A-mediated LPC/LPA axis.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: December 24, 2025
Gut Microbiota and Metabolomics Insights into the Gualou-Xiebai Herb Pair for Dyslipidemia and Atherosclerosis.
Journal: Journal of microbiology and biotechnology
Published: October 17, 2025
The regulation of lymphatic valve formation promotes lymphatic drainage to reduce atherosclerotic plaques: A novel mechanism of anti-atherosclerosis by Gualou-Xiebai.
Journal: Journal of ethnopharmacology
Published: May 14, 2025
Extract of Gualou-Xiebai Herb Pair Improves Lipid Metabolism Disorders by Enhancing the Reverse Cholesterol Transport in Atherosclerosis Mice.
Journal: Current neurovascular research
Published: February 01, 2024
Gualou-Xiebai herb pair ameliorate atherosclerosis in HFD-induced ApoE-/- mice and inhibit the ox-LDL-induced injury of HUVECs by regulating the Nrf2-mediated ferroptosis.
Journal: Journal of ethnopharmacology
Published: November 13, 2023
Gualou-Xiebai herb pair and its active ingredients act against atherosclerosis by suppressing VSMC-derived foam cell formation via regulating P2RY12-mediated lipophagy.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: October 23, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026